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Objective: To characterise ARGS neoepitope concentrations in various matrices from patients with knee
osteoarthritis (OA) and assess performance of an immunoassay to facilitate clinical development
of therapeutics affecting the A disintegrin and metalloproteinase with thrombospondin motifs 5
(ADAMTS-5) pathway.
Design: Matched sera, urine, and synovial ﬂuid (SF) (surgical subjects only) were collected from healthy
subjects, subjects with knee OA (non-surgical OA), and OA subjects undergoing total knee replacement
(OA-TKR; n ¼ 20 per group). Diurnal and inter-day variation was evaluated in the non-surgical OA group
over 3 separate visits. Serum and urine samples were collected on two visits for the OA-TKR group with
SF taken only at the time of surgery. ARGS neoepitope was quantitated using an optimized immunoassay.
Results: Serum ARGS neoepitope concentrations were elevated in OA-TKR subjects compared to non-
surgical OA subjects (P ¼ 0.005) and healthy subjects (P ¼ 0.0002). Creatinine corrected urinary ARGS
neoepitope concentrations were more variable, but were also elevated in the OA-TKR subjects compared
to healthy subjects (P ¼ 0.008). No signiﬁcant diurnal effect or inter-day variance was observed in serum
or urine. Serum ARGS neoepitope concentrations correlated with age (P ¼ 0.0252) but not with total
number of joints with OA involvement. SF ARGS neoepitope concentrations correlated with Western
Ontario and MacMaster OA Index (WOMAC) stiffness score (P ¼ 0.04) whereas a weaker, non-signiﬁcant
trend towards positive correlation with combined WOMAC score and the number of concurrent joints
was observed.
Conclusions: This study utilized a sensitive and robust assay to evaluate ARGS neoepitope concentrations
in various matrices in OA patients and healthy volunteers. ARGS neoepitope appears promising as a
prognostic/stratiﬁcation marker to facilitate patient selection and as an early pharmacodynamic marker
for OA therapeutic trials.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Characterizing the pathological processes involved in osteoar-
thritic cartilage degradation has been a signiﬁcant focus of research
over the past few decades with the ultimate goals of identifying key
factors involved and development of novel osteoarthritis (OA)
treatment strategies. Through the use of knockout mouse strains its to: F.M. Germaschewski,
e, GlaxoSmithKline, Gunnels
0)-1438-76-2641.
(F.M. Germaschewski).
ternational. Published by Elsevier Lhas been widely reported that A disintegrin and metalloproteinase
with thrombospondin motifs 5 (ADAMTS-5) is an instrumental
protease responsible for driving cartilage loss in preclinical models
of arthritis1e3. Further studies assessing the ability of fully selective,
high afﬁnity ADAMTS-4 and ADAMTS-5 antibodies to neutralise
recombinant and native aggrecanase activity and modulate disease
related endpoints in in vivo and ex-vivo models has conﬁrmed
ADAMTS-5 is a major protease involved in human OA4. To monitor
the pharmacodynamic effect of a humanised anti-ADAMTS-5
monoclonal antibody (GSK2394002) as a potential disease modi-
fying agent for OA, an assay that can quantify concentrations of the
ARGS neoepitope, a product of ADAMTS-5 enzymatic degradationtd. All rights reserved.
Table I
Subject demographics
Subject
number
Age (years)
(mean  S.E.M.)
Gender
(female:male)
Visits Samples
Healthy
controls*
20 64.1  1.3 12:8 1 Serum, urine
OA 20 66.5  1.6 12:8 1y Serum, urine
2, 3 Serum, urine
OA-TKR 20 68.7  2.5 12:8 1 Serum, urine
2 Serum, urine, SF
S.E.M.: Standard error of the mean.
* Subjects without signs or symptoms of OA or previous diagnosis of OA.
y Samples collected at ﬁve timepoints during the day. All other samples collected
at 9:00 am.
Table II
Summary of OA history
OA history* OA
(n ¼ 20)
OA-TKR
(n ¼ 20)
Knees affected by OA (% subjects)
Both 75 70
Left 5 e
Right 20 30
OA in joints other than the affected knee(s) (%) 60 60
Average number of OA jointsy 2.8 3.5
Concurrent hand OA (% subjects) 50 30
Concurrent foot OA (% subjects) 15 20
Concurrent hip OA (% subjects) 10 30
Concurrent spine OA (% subjects) 5 20
Concurrent shoulder OA (% subjects) 5 25
Knee injury within 30 days* 0 0
Disease duration (mean years  S.E.M.) 9.0  1.9 8.2  1.2
Combined WOMAC (visual analogue
100 mm scale, mean  S.E.M.)
26.1  1.9 55.2  4.45
* Based on subjects’ self report.
y OA joints are counted using all the effected joints including the affected knee(s),
1 for single OA knee and 2 for both OA knees.
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made over previous assays7e11 to reduce matrix effects and in-
crease sensitivity by inclusion of additional blocking steps and
ARGS neoepitope matrix depletion for standard curve dilutions. In
addition the dynamic range has been increased over previous
enzyme linked immunosorbent assay (ELISA) assays.
In this observational study, we evaluated ARGS neoepitope in
patients with knee OA to support development of GSK2394002 and
other drugs, which may affect cartilage degradation. Particular
focus was to characterize the ARGS neoepitope assay performance
and relative concentrations of ARGS neoepitope in blood, synovial
ﬂuid (SF) and urine of patients with knee OA managed conserva-
tively (conﬁrmed by X-ray but not scheduled or anticipated to
require joint replacement in the coming year), or with end-stage
knee OA undergoing TKR. Secondary objectives were to investi-
gate diurnal, between- and within-subject variability of ARGS
neoepitope. In addition correlations between serum and SF and to
other demographic or clinical factors were assessed. An additional
set of samples, obtained from age- and sex-matched healthy vol-
unteers, served as a control group for comparative purposes.
Data from this study are intended to inform the biomarker
strategy and study design of disease modifying treatments for OA.
In addition, measurement of the ARGS neoepitope could serve as a
prognostic or stratiﬁcation marker to identify patient subsets more
likely to respond to and beneﬁt from treatment12.
Materials and methods
Subject samples
Human biological samples were obtained with written
informed consent from individuals in accordance with Interna-
tional Conference on Harmonisation Good Laboratory Practice (ICH
GCP) under a protocol approved by the UK National Research Ethics
Committee (Essex) (Registry No. 10/H0301/61, GSK ADM114261).
Subjects who had knee OA that was not end-stage (n¼ 20) were
recruited from the GSK clinical unit (Cambridge, UK). Conﬁrmation
of knee OA was based on X-ray reports from General Practitioners
or hospital opinion letters where possible or MR scan ﬁndings were
accepted if accompanied by a specialist opinion indicating a diag-
nosis of knee OA. If none of these were available then a conﬁrma-
tory X-ray was performed. Biological samples were collected on
three visits in this cohort. On visit 1, subjects provided blood and
urine samples at 5 timepoints between the hours of 0800 and 1,800
to assess diurnal variation. Single morning donation of blood and
urine was obtained on visits 2 and 3. Approximately 1e2 weeks
separated each study visit.
OA subjects undergoing total knee replacement (TKR) (n ¼ 20)
were recruited from the Robert Jones and Agnes Hunt Orthopaedic
Hospital (Oswestry, UK). Biological samples were provided on two
visits corresponding to the subjects’ scheduled pre-surgical visit
(visit 1) that typically took place between 3 and 6 weeks prior to
surgery, and on the day of TKR (visit 2). On visit 1, matched blood
and urine were collected. On visit 2, matched blood, urine and SF
were collected. OA history was obtained from each OA patient at
screening along with a subject completed WOMAC questionnaire13
(Table II). Matched serum and urine were obtained via commercial
sources (Tissue Solutions, Glasgow, UK; Cambridge Bioscience,
Cambridge, UK) from 20 age- and sex-matched healthy individuals.
This sample set served as a non-OA reference group.
Materials
Human recombinant ADAMTS-5 was generated by Glax-
oSmithKline14. Recombinant human aggrecan (G1-IGD-G2domains) was purchased from R&D systems (Minneapolis, USA).
The mouse monoclonal anti human aggrecan antibody (binding to
globular domains 1 and 2 (G1 and G2) of human aggrecan was
purchased from Invitrogen (Carlsbad, USA). The monoclonal anti-
body, OA-1, which recognizes an N-terminal neoepitope ‘374ARGS’
(ARGS) following aggrecanase cleavage of the interglobular domain
(IGD) of aggrecan, was developed at GSK7 Standard bind Meso-
scale-discovery (MSD) 96-well microtitre plates, blocker A, cyto-
kine assay diluents, antibody diluents, 4 read buffer T with sur-
factant, sulfo-TAG normal human serum (NHS) ester and the Sector
Imager 6000 with Discovery Workbench software were obtained
from Meso Scale Discovery (MSD, Gaithersburg, USA).
Generation of ARGS neoepitope standard
A complete ADAMTS-5 digest of recombinant human aggrecan
IGD (R&D Systems, Minneapolis, USA) was prepared and used as a
standard for quantiﬁcation of samples with the ARGS neoepitope
assay. 50 mL of 1 mg/mL aggrecan was digested with 2.25 mL of
1.2 mM ADAMTS-5 in 10 mM hydroxyethyl piper-
azineethanesulfonic acid (HEPES), 1 mM CaCl2, 150 mM NaCl2,
0.05% NP-40, 1 mM ZnCl2 at pH 7.4 for 4 days at 37C. Complete
digestion was conﬁrmed by protein fragmentation Sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting according to published methods7. In the absence
of aggrecanase treatment a singlew92 kD band is observed, while
58 kD NITEGE and diffuse w52 kD ARGS neoepitope speciﬁc
immunoreactive bands arise following ADAMTS-5 mediated
digestion (Supplementary Fig. 1).
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ARGS neoepitope is present in serum, urine and SF from healthy
subjects6,9,15, hence there was a requirement to remove the neo-
epitope from pooled matrices for standard curve dilutions. ARGS
was removed from matrices by immobilization on NHS-sepharose
using the OA-1 antibody as a capture reagent. OA-1 monoclonal
antibody was buffer-exchanged on a Fast Desalting column into
bicarbonate buffer (200 mM NaHCO3, 500 mM NaCl, pH 8.3) and
immobilised to 5 mL NHS-activated sepharose. Unreacted groups
on the resinwere blocked in 0.5M Ethanolamine, 0.5MNaCl buffer,
pH 8.3. The resin was packed into the column and washed
repeatedly with alternative high pH (0.1 M TriseHCl, pH 8.5) and
low pH buffers (0.1 M Acetate, 0.5 M NaCl, pH 5.0) then equilibrated
in phosphate buffered saline (PBS). Pooled healthy human serum,
urine or pooled rheumatoid arthritis (RA) SF (500 mL each) was
passed over the column and dispensed.Measurement of ARGS neoepitope by electrochemiluminscence
assay
Concentrations of ARGS neoepitope were measured using
electrochemiluminescence (ECL) technology on the MSD plat-
form16. Standard bind MSD plates were spot coated using a Mos-
quito HTS liquid handler with 1 mL of 25 mg/mL anti human
aggrecan antibody (Invitrogen, USA) in 25 mM HEPES, 0.015%
triton-X-100. Plates were allowed to dry uncovered at room tem-
perature. Following 3  175 mL washes with PBS 0.05% Tween 20
(PBST) plates were incubated with 150 mL of 3% MSD blocker A and
incubated at room temperature for 1 h on a shaker set to 600 rpm.
Following 3  175 mL washes with PBST, 25 mL/well of MSD human
cytokine assay diluent was added to all wells and incubated at room
temperature for 30 min on a shaker set to 600 rpm. ARGS neo-
epitope standard curve (1,000e0.98 ng/mL) was prepared using
ARGS neoepitope depleted matrix. Duplicates of 25 mL of standards
or neat samples were added to the plates making a total assay
volume of 50 mL/well and incubated for 2 h at room temperature on
a shaker. After washing, plates were incubated at room tempera-
ture with 25 ml/well of 1 mg/mL directly labelled sulfo-TAG-OA-1
mAb diluted in MSD antibody diluent. After a ﬁnal wash, 150 mL/
well of 4 read buffer diluted 1:2 inMilliporewater was added, and
plates read in a Sector Imager 6000. Samples concentrations of
ARGS neoepitope were calculated from the standard curve (four-
parameter logistic) using XLﬁt. Five quality controls (ARGS depleted
serum spiked with ﬁve concentrations of ARGS) were included on
all plates and tested in triplicate.Table III
Validation parameters of the ARGS neoepitope assay
Serum Urine SF
Standard curve precision LLOQ (ng/mL) 1.37 0.46 1.95
Standard curve precision LOD (ng/mL) 0.80 0.40 0.51
Linear range of standard (ng/mL) 0.98e1000 ng/mL
Intra assay % CV (n ¼ 5, 6 replicates) 12%
Inter assay % CV (n ¼ 5, 3 replicates,
5 assays)
10%
Cross plate precision % CV 14%
Accuracy % CV, RE (n ¼ 3, 3 replicates,
3 assays)
30%
Matrix effects % RE (n ¼ 10 serum,
n ¼ 10 urine, n ¼ 5 SF)
18% serum; 30% SF;
77% urine
Stability % RE (n ¼ 4, 3x FT, RT 24 h,
2e8C 24 h)
20% serum; 30% SF
Linearity of dilution % RE (n ¼ 2) 20%: 1:32 (spiked);
1:8 (unspiked)
LLOQ: lower limit of quantiﬁcation; FT: freeze thaw.Sample treatment and normalisation of ARGS neoepitope
concentrations
SF was aspirated directly without lavage (neat) and volume of
aspirate recorded at time of surgery then treated with hyaluroni-
dase to reduce viscosity. Sigma Type IV-S hyaluronidase (Sigma, St
Louis, USA) was prepared at 100 U/mL in PBS and 10 mL added to
each 1 mL of SF to give a ﬁnal concentration of 1 U/mL hyaluroni-
dase. SF samples were put on a roller for 1 h at room temperature
then spun at 1,000 rpm for 10min room temperature and ﬂocculate
matter removed followed by a spin at 2,500 rpm for 10 min at room
temperature. SF supernatant was stored at 80C before testing
undiluted in the ARGS assay. Creatinine concentrations in urine
samples were determined using an enzymatic U-creat-Kone assay
(Thermo Fisher Scientiﬁc, Massachusetts, USA).Statistical analysis
This was an exploratory biomarker study thus no formal sta-
tistical hypothesis was tested. Analysis of variance (ANOVA)models
were used to analyse the serum ARGS neoepitope concentrations
between OA, OA-TKR, and age- and sex-matched healthy control
cohorts. Multiplicity issue due to multiple comparisons was cor-
rected using Tukey’s method. Statistical linear correlation analyses
were performed between blood and SF ARGS neoepitope concen-
trations (OA-TKR cohort) using Pearson analysis. In addition,
diurnal and inter-day variability were calculated. Additional cor-
relation analyses between ARGS neoepitope and secondary bio-
markers of age, number of affected joints and Western Ontario and
MacMaster OA Index (WOMAC) were performed. Appropriate data
transformations were utilised for datawhere normality assumption
were violated.
Results
Subject demographics
Sex was well matched across the three groups (Table I). Age was
comparable across the three groups (P-value ¼ 0.2218), with the
OA-TKR group being slightly older (mean age 68.7 years) than the
OA group (mean age 66.5 years) or healthy volunteer group (mean
age 64.1 years). All OA patients were white/Caucasian and selected
based on having no known knee injury within the last 30 days. The
reference healthy controls were 90% white/Caucasian, and were
without signs or symptoms of OA or any previous diagnosis of OA.
OA-TKR patients had signiﬁcantly higher WOMAC scores for pain,
stiffness and physical function than OA patients not undergoing
joint replacement therapy (Table II).
Technical performance of the ARGS neoepitope assay
The ARGS neoepitope assay was optimised over previous as-
says7e11 to reduce matrix effects and increase the dynamic range
and sensitivity by inclusion of additional blocking steps (MSD
blocker A and cytokine diluent) and ARGS neoepitope matrix
depletion for standard curve dilutions. To evaluate the precision of
the standard curve, the ARGS neoepitope standard was analysed in
ARGS neoepitope depleted serum, urine or SF in replicates of 2 in 7
independent runs. The cumulative mean of all 7 runs of the stan-
dard in each matrix was  15% relative error (RE) and coefﬁcient
of variation (CV), 20% RE and CV for samples 1e2 the lower or
upper limit of quantitation (LLOQ, ULOQ) (Table III, Supplementary
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and intra assay variability of serum samples. Intra assay CV was
12% (n ¼ 5 samples, three replicates, three runs), the inter assay
CV calculated from testing ﬁve samples in triplicate on three runs
was 10%. To monitor plate column, row and corner to corner
variation (cross plate precision) a single sample was tested in all
wells of a 96-well plate and CVwas14% across all wells Accuracy
was determined by assessing recovery of freshly spiked standard at
three concentrations into ARGS neoepitope depleted serum17.
Percent CV for 2 out of 3 spiked samples tested in three assays was
10% and % RE was 30%. Matrix effects were evaluated by
comparing unspiked with 50 ng/mL freshly spiked ARGS neo-
epitope into healthy donor serum, urine and OA SF. Spiked recovery
was 18% RE for serum (n ¼ 10), 30% RE SF (n ¼ 5). Spiked
recovery in urine was 77% RE. Stability for 3 freeze/thaws, RT
or 2e8C for 24 h was 20% for urine and serum and 30% for
SF. Linearity of dilution was conducted in unspiked and 500 ng/mL
ARGS neoepitope spiked healthy serum samples (n ¼ 2 replicates, 1
run). Assay was linear to 1:4 dilution with spiked samples and 1:4
with unspiked (20% RE) (Table III, Supplementary Table 2).
ARGS neoepitope concentration in different study populations
Signiﬁcantly higher serum concentrations of ARGS neoepitope
were measured in OA-TKR patients compared to OA patients
(P ¼ 0.01) and vs healthy subjects (P ¼ 0.0002) but no differences
were observed between OA and healthy (P¼ 0.32) [Fig.1]. Similarly,
urinary ARGS neoepitope concentrations (corrected for creatinine)
were signiﬁcantly higher in the OA-TKR patients compared to OA
patients (P ¼ 0.001).
ARGS neoepitope intra and inter-day variability
Analysis of intra-day (diurnal) serum ARGS neoepitope variation
carried out in OA patients on visit 1 showed no signiﬁcant differ-
ence at any of the ﬁve timepoints measured (0800, 0900, 1,200,Fig. 1. Comparison of serum ARGS neoepitope concentrations (ng/mL) in healthy
(n ¼ 20), OA (n ¼ 20) and OA-TKR (n ¼ 20). OA subject data is the mean value from all
individuals from all visits. Shaded box represents median and 25%/75% percentile,
whiskers represent the min/max of ARGS neoepitope values across the 20 subjects in
each group, circles represent mean values. Results show a signiﬁcant difference be-
tween OA-TKR and healthy (***P ¼ 0.0002) and between OA-TKR and OA (**P ¼ 0.01).1,500, 1,800), (P ¼ 0.99, CV 12%). Assessment of serum ARGS neo-
epitope concentrations across the three visits (0900 sample) also
showed that inter-day concentrations were relatively constant over
the time frame studied (P ¼ 0.71, CV 25%) [Fig. 2(a), (b)].
Over a third of urine samples tested had ARGS neoepitope
concentrations below the LLOQ of the assay so for these samples, a
value of half the LLOQ was substituted. Urine ARGS neoepitope
concentrations were corrected using creatinine to account for dif-
ferences in urine volume. Higher subject variability in creatinine
corrected ARGS neoepitope concentrations was observed in urine
compared to ARGS neoepitope concentrations in matched serum as
shown by higher % especially within-subjects but, similar to serum,
in urine there was no signiﬁcant intra-day variation (P ¼ 0.84, CV
36%) or inter-day ARGS neoepitope variation overall (P ¼ 0.58, CV
46%) [Fig. 2(c), (d)]. ARGS neoepitope concentrations in serum and
urine (creatinine corrected) from OA-TKR subjects between visits 1
and 2 also showed no signiﬁcant inter-day variation (P ¼ 0.75 and
P ¼ 0.62 for serum and creatinine corrected urine respectively)
(data not shown).
ARGS neoepitope correlation analyses
Statistical analyses were conducted to determine correlations
between matrices or to other patient characteristics or clinical pa-
rameters. There was no signiﬁcant correlation between serum vs
synovial ARGS neoepitope concentrations (r ¼ 0.17, P¼ 0.50) [Fig. 3]
or between serum vs total synovial ARGS neoepitope relative to the
volumeof SFcollected (r¼0.39,P¼0.11) (datanot shown). Itwasalso
shown that there was a signiﬁcant correlation (r ¼ 0.64,P ¼ 0.003)
between serum ARGS and creatinine corrected urine ARGS in the
TKR-OA group but not in the OA group (r ¼ 0.35, P ¼ 0.13).
Serum ARGS neoepitope concentrations were positively corre-
lated with age in the OA (r ¼ 0.50, P ¼ 0.03) and OA-TKR cohorts
(r ¼ 0.54, P ¼ 0.01) [Fig. 4] but no correlation was observed in
healthy subjects between ARGS neoepitope and age (r ¼ 0.03,
P ¼ 0.88) (data not shown). A signiﬁcant correlation of creatinine
corrected urine ARGS neoepitope with age was also observed with
strongest correlation seen in the OA-TKR subjects (r ¼ 0.56,
P ¼ 0.01).
SF ARGS neoepitope concentrations showed a trend towards
correlation with age and also to the number of concurrent joints
with OA, but these correlations were not signiﬁcant. SF showed no
signiﬁcant correlation with the combined WOMAC score (pain,
stiffness and physical) (r ¼ 0.38, P ¼ 0.12) [Fig. 4]. No differences
based on sex (males vs females) were observed with any of the
matrices in either the OA or OA-TKR subjects (data not shown).
Discussion
Due to the slow and variable course of OA disease progression as
measured by radiographic endpoints, it is important to identify
biomarkers which may serve as early markers of drug activity in
clinical trials. ARGS neoepitope is a degradation product of aggre-
canase activity, speciﬁcally of ADAMTS-4 and ADAMTS-5, two en-
zymes implicated in OA pathogenesis. As such, ARGS neoepitope is
potential marker of disease activity and response to treatments
affecting ADAMTS-4/5 or upstream targets. Previous assays have
been reported to measure ARGS neoepitope7e11. In the present
study we evaluated an optimized ARGS neoepitope assay utilising
the OA-1 neoepitope antibody on the MSD platform using ARGS
neoepitope depleted matrices for dilution of the standard curves.
This has resulted in lower matrix backgrounds and more accurate
sample back calculations from the standard curve. Together with
additional blocking steps, minimal matrix interference has been
observed with serum, urine and SF allowing samples to be tested
Fig. 2. (a) Analysis of mean diurnal (hours) and inter-day variation on visits 1e3 (V1e3) in ARGS neoepitope concentrations levels (ng/mL) from duplicate serum samples from
individual OA patients (n ¼ 20 subjects). (b) Serum ARGS neoepitope concentrations presented as box and whiskers plot. Shaded box represents median and 25%/75% percentile,
whiskers represent the min/max of ARGS neoepitope values across the 20 subjects in each group, circles represents mean values. Results show no signiﬁcant diurnal or inter-day
variability either in mean serum ARGS neoepitope concentrations or intra subject concentrations over time (P > 0.05). (c) Analysis of mean diurnal (hours) and inter-day variation
on visits 1e3 (V1e3) in ARGS neoepitope concentrations levels (ng/mmol) from duplicate creatinine corrected urine samples from individual OA patients (n ¼ 20 subjects). (d)
Creatinine corrected urine ARGS neoepitope concentrations presented as box and whiskers plot. Shaded box represents median and 25%/75% percentile, whiskers represent the
min/max of ARGS neoepitope values across the 20 subjects in each group, circles represents mean values. Results show no signiﬁcant diurnal or inter-day variability either in mean
creatinine corrected urine ARGS neoepitope concentrations or intra subject concentrations over time (P > 0.05).
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improved over other assays, the ability to test neat samples makes
it feasible to measure ARGS at lower concentrations in patient
samples. The dynamic range has also been signiﬁcantly improved
over previous versions of the assay so all samples could be tested
undiluted and had readings below the ULOQ of the assay.
As part of the sample preparation, SF samples were treated with
hyaluronidase to reduce viscosity with the aim of improving assay
precision and signal. Although not speciﬁcally evaluated herein,
recent external data suggest this step may not be an absolute
requirement for measurements using MSD technology18 and more
speciﬁcally measurement of ARGS neoepitope by ECL assay11.
However, evaluation of the effect of hyaluronidase pre-treatment
on SF ARGS neoepitope concentrations using the present assay
format would be required to deﬁnitively guide exclusion of this step
for future studies.
In principle, determination of markers in SF from the target joint
would be expected to provide a more accurate indication of diseaseactivity in the target joint compared to serum, urine, or other
‘systemic’ matrix. However, SF is less amenable to sampling in the
clinic and is especially difﬁcult to obtain in settings other than knee
OA. Furthermore, accurate quantitation of SF markers presents
certain challenges due to technical issues and interpretation of SF
marker concentrations can be confounded by dilution in the pres-
ence of effusion. Therefore, we were interested in testing ARGS
neoepitope concentrations in other biological ﬂuids to understand
the feasibility of utilising serum, urine or both types of samples in a
clinical study and evaluate whether they correlate with SF con-
centrations from the same subject.
Mean serumARGS neoepitope concentrations were higher in OA
patients than healthy subjects (this difference was not statistically
signiﬁcant), yet were higher still in the OA-TKR group (this differ-
ence was statistically signiﬁcant compared to both OA subjects and
healthy subjects). The data showing elevated serum ARGS neo-
epitope concentrations in OA patients conﬁrms results from other
studies9,10,19. The elevation of ARGS neoepitope in OA-TKR over OA
Fig. 3. Correlation plot between serum (mean ng/mL from two duplicate samples from
each donor) and synovial ARGS neoepitope shows no signiﬁcant linear correlation
(P ¼ 0.50, r ¼ 0.17). The linear ﬁt and 95% conﬁdence interval are shown in the plot.
Matched serum and SF from OA-TKR subjects with measurable SF (n ¼ 18).
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sion and aggrecan degradation is likely an ongoing process
throughout the disease course.
Creatinine corrected urine ARGS neoepitope concentrations
were similar to, although more variable than, serum concentra-
tions; increased urinary ARGS neoepitope concentrations were
observed in the OA-TKR group compared to OA and healthy sub-
jects. The lack of difference in urinary ARGS neoepitope concen-
trations between subjects with OA and no OA is consistent with
previous ARGS neoepitope ELISA data utilising an afﬁnity matured
form of the BC3 ARGS neoepitope antibody9,20. Based on the higher
variability of urinary ARGS neopepitope concentrations, increased
matrix effects and lower resolution to distinguish among the co-
horts evaluated (compared to serum), we propose the use of serum
rather than urine as the preferred matrix to assess systemic con-
centrations of ARGS neoepitope.
To our knowledge this is the ﬁrst study to evaluate potential
diurnal variation of ARGS neoepitope; no signiﬁcant diurnal vari-
ation was observed in either serum or urine of OA patients. In
addition, within-subject serum and urine ARGS neoepitope con-
centrations were stable across the 2 (TKA-OA cohort) or three study
visits (OA patients), a time period that spanned approximately 6
weeks. These results are in good agreement with previous results in
mild/moderate OA patients where samples were collected at
baseline, 2 and 4 weeks9. In this study variation in SF was not
assessed but it is likelymore variation may be observed particularly
immediately after knee injury21. The lack of diurnal variation, and
relative stability of within-subject ARGS neoepitope repeatedly
measured over the course of weeks, has important practical im-
plications for study design. Speciﬁcally, these data suggest that
time of day of sample collection should not impact results, and
there is not a necessity to have patients come in for sample pro-
curements within a narrow time interval each study visit.
In patients undergoing TKR, ARGS neoepitope concentrations
measured in SF (taken at time of surgery) were compared to serum
(from a blood samples taken on the day of surgery), and there waslittle correlation between the two matrices. The observation that
serum concentration of ARGS neoepitope is not an accurate sur-
rogate for knee SF concentration presents a strategic and inter-
pretation challenge for development of drugs which impact the
aggrecanase pathway. As the present study was not interventional,
we were unable to test whether the correlationwould be increased
under conditions of pre- and post-administration of an ADAMTS-5
inhibitor. Nonetheless, even if correlation to a single joint is low, it
is reasonable to expect that serum ARGS neoepitope concentration
is a more accurate marker of ‘total body’ aggrecanase activity
compared to SF data from a single joint. From this standpoint,
serum ARGS neoepitope may be a valuable marker for following
multi-joint disease and as a pharmacodynamic marker following
systemic administration of aggrecanase inhibitors. Supporting this
position, in preclinical studies in vivo, we have observed dose-
dependent reductions in serum ARGS neoepitope concentrations
following systemic administration of a speciﬁc inhibitor of
ADAMTS-5 (unpublished data), suggesting that serum ARGS neo-
epitope concentration may be a useful pharmacodynamic marker
of target engagement/target inhibition. Whether changes in a
‘systemic’ marker would reﬂect PD in a single target joint is a key
unanswered question.
Pre-planned exploratory statistical analyses revealed several
associations of note. There was a signiﬁcant correlation between
age and serum ARGS neoepitope concentration in both the OA and
OA-TKR patients, and a trend for a positive correlation of age with
SF ARGS neoepitope concentration. Given that age is one of the
greatest risk factors for OA this is perhaps not surprising22. No
differences were found between males and females in any of the
matrices. Earlier studies observed increased SF ARGS neoepitope
concentrations in males over females in OA patients, but no cor-
relationwith age, in patients with radiographic progression of knee
OA11. Interestingly, SF ARGS neoepitope concentrations in the OA-
TKR patients showed a mild positive correlation to the WOMAC
stiffness score and a trend to positive correlation to the combined
WOMAC score. These results may reﬂect an underlying correlation
between index knee symptoms and index knee aggrecanase ac-
tivity. No statistical correlations were observed between SF and
serum or urine concentrations of ARGS neoepitope suggesting
neither serum nor urine accurately reﬂect local levels in the index
joint. However, higher numbers of patient samples and longitudi-
nal sampling would be required to help build conﬁdence in these
observations and how they may relate to radiographic damage and
other biochemical markers.
Limitations of this study include the relatively small sample size
per cohort; independent evaluation would be required to conﬁrm
the associations observed from the exploratory statistical analyses.
The present study relied predominantly on X-ray based determi-
nation of OA. New higher resolution MR imaging modalities such as
T7 dGEMRIC, 23N and gagCEST may prove to be a more sensitive
measure of cartilage pathology and stronger clinical correlate than
symptoms and radiographic measures. Furthermore, in the current
study it was unknown if all the surgical OA patients had macro-
scopic cartilage changes, to what extent and whether ARGS neo-
epitope concentrations differed between patients ranging from
moderate to extensive cartilage erosion, as parallel imaging of
cartilage integrity was not performed/available in all cases. Further
studies would be required to investigate whether ARGS neoepitope
concentrations reﬂect ongoing cartilage damage, and therefore
require the presence of some preserved cartilage.
In conclusion, testing of patient samples in this study have
demonstrated the ARGS neoepitope assay is sufﬁciently validated
for measuring ARGS neoepitope in different matrices and patient
populations and has the potential to serve as a pharmacodynamic
read-out for aggrecanase inhibitors or other disease modifying
Fig. 4. Correlation between serum or synovial ARGS neoepitope or creatinine corrected ARGS neoepitope (mean ng/mL from two duplicate samples) vs subject age, number of
concurrent OA joints and combined WOMAC score (pain, stiffness, physical). Data presented from age and sex-matched OA serum and urine (blue O) (n ¼ 20) and OA-TKR matched
serum and urine (red þ) (n ¼ 20) and OA-TKR subjects with measurable SF (n ¼ 18). Data was Log10 transformed and shows correlation of serum ARGS neoepitope vs age in both OA
and OA-TKR groups (P ¼ 0.03, P ¼ 0.01 respectively). A signiﬁcant correlation of creatinine corrected ARGS with age was observed which was strongest in the OA-TKR subjects
(r ¼ 0.56, P ¼ 0.01). Mild correlations were observed between SF ARGS and the number of concurrent OA joints (P ¼ 0.14) and total WOMAC (P ¼ 0.12). Regression analysis with
Pearson’s correlation coefﬁcient.
F.M. Germaschewski et al. / Osteoarthritis and Cartilage 22 (2014) 690e697696osteoarthritic drugs that impact aggrecanase activity. Further
studies to investigate correlation of ARGS neoepitope with other
biochemical and/or imaging biomarkers may identify a useful
signature of disease for stratiﬁcation of patients in future clinical
studies as well as the potential to act as a prognostic indicator of
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